DevsHealth
DevsHealth is a DeepTech company dedicated to revolutionizing drug development for infectious diseases through AI, real-world data, and molecular modeling. Their mission is to provide ultra-fast solutions to global health challenges, building the largest drug pipeline for infectious diseases and making treatments more accessible and effective. They focus on developing new antibiotics and antivirals, collaborating with research institutes, and leveraging advanced technology to accelerate discovery and reduce costs.
Industries
Nr. of Employees
small (1-50)
Products
Computational drug discovery platform
A DeepTech software platform that integrates AI, molecular modelling and data analytics to generate and prioritise novel small‑molecule candidates for anti‑infective indications.
In‑house anti‑infective preclinical pipeline
A pipeline of preclinical small‑molecule candidates targeting bacterial and viral infectious diseases, including projects for COVID‑19 oral treatment, broad‑spectrum flavivirus antivirals and antibiotics against multi‑resistant Staphylococcus aureus.
Computational drug discovery platform
A DeepTech software platform that integrates AI, molecular modelling and data analytics to generate and prioritise novel small‑molecule candidates for anti‑infective indications.
In‑house anti‑infective preclinical pipeline
A pipeline of preclinical small‑molecule candidates targeting bacterial and viral infectious diseases, including projects for COVID‑19 oral treatment, broad‑spectrum flavivirus antivirals and antibiotics against multi‑resistant Staphylococcus aureus.
Services
Computational drug discovery and virtual screening
In silico screening, molecular design and prioritisation of small‑molecule candidates using AI and molecular modelling.
Project management and co-development
End‑to‑end project coordination, KOL engagement and co‑development agreements to advance candidates from discovery to early clinical stages.
Chemical synthesis coordination and outsourcing management
Management of external synthesis providers under success‑based or performance payment models to produce candidate compounds.
Access coordination for in vitro / in vivo testing
Organisation and coordination of partner‑led biological testing, including BSL2/BSL3 workflows, for preclinical validation.
Spin‑out formation and early‑stage incubation
Establishment and management of spin‑out entities to host specific drug projects and carry out fundraising and early clinical development.
In‑kind R&D support programme for antibiotic projects
Discounted computational and discovery services offered as in‑kind investment to early‑stage antibiotic projects selected through a programme.
Computational drug discovery and virtual screening
In silico screening, molecular design and prioritisation of small‑molecule candidates using AI and molecular modelling.
Project management and co-development
End‑to‑end project coordination, KOL engagement and co‑development agreements to advance candidates from discovery to early clinical stages.
Chemical synthesis coordination and outsourcing management
Management of external synthesis providers under success‑based or performance payment models to produce candidate compounds.
Access coordination for in vitro / in vivo testing
Organisation and coordination of partner‑led biological testing, including BSL2/BSL3 workflows, for preclinical validation.
Spin‑out formation and early‑stage incubation
Establishment and management of spin‑out entities to host specific drug projects and carry out fundraising and early clinical development.
In‑kind R&D support programme for antibiotic projects
Discounted computational and discovery services offered as in‑kind investment to early‑stage antibiotic projects selected through a programme.
Expertise Areas
- AI-driven drug discovery
- Antibacterial and antiviral small-molecule discovery
- Computational chemistry and molecular modelling
- Real‑world data analytics for drug design
Key Technologies
- Machine learning / AI for medicinal chemistry
- Molecular docking and protein–ligand modelling
- ADME/Tox in silico prediction models
- High‑throughput virtual screening